Rahardini Elda Putri, Ikeda Koji, Nugroho Dhite Bayu, Hirata Ken-Ichi, Emoto Noriaki
Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, 4-19-1 Motoyamakita, Higashinada, Kobe 658-8558, Japan.
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe 650-0017, Japan.
Kobe J Med Sci. 2020 Jan 20;65(3):E100-E109.
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with poor prognosis due to limited clinical treatment options. IPF is characterized by the augmented deposition of extracellular matrix driven by myofibroblasts, and the epithelial-mesenchymal transition (EMT) has been known to play an essential role in the mechanism of pulmonary fibrosis. Previous genome-wide association study identified Fam13a as one of genes that showed genetic link with IPF and chronic obstructive pulmonary disease. Here, we analyzed the role of Fam13a in the pathogenesis of pulmonary fibrosis using Fam13a-deficient mice. We found that Fam13a was down-regulated in mouse lungs of bleomycin-induced pulmonary fibrosis model. Of note, genetic deletion of Fam13a exacerbated the lung fibrosis induced by bleomycin in association with enhanced EMT in mice. Moreover, silencing of Fam13a accelerated EMT induced by TGF-β and TNF-α in alveolar epithelial cells, accompanied by increased active β-catenin and its nuclear accumulation. Our data revealed a crucial role of Fam13a in the development of pulmonary fibrosis potentially through inhibiting EMT, and thus Fam13a has a therapeutic potential in the treatment of IPF.
特发性肺纤维化(IPF)是一种预后较差的毁灭性疾病,因为临床治疗选择有限。IPF的特征是由肌成纤维细胞驱动的细胞外基质沉积增加,并且已知上皮-间质转化(EMT)在肺纤维化机制中起重要作用。先前的全基因组关联研究确定Fam13a是与IPF和慢性阻塞性肺疾病存在遗传关联的基因之一。在此,我们使用Fam13a基因缺失小鼠分析了Fam13a在肺纤维化发病机制中的作用。我们发现Fam13a在博莱霉素诱导的肺纤维化模型小鼠肺中表达下调。值得注意的是,Fam13a基因缺失加剧了博莱霉素诱导的小鼠肺纤维化,并伴有小鼠EMT增强。此外,Fam13a沉默加速了转化生长因子-β(TGF-β)和肿瘤坏死因子-α(TNF-α)诱导的肺泡上皮细胞EMT,同时伴有活性β-连环蛋白增加及其核内积累。我们的数据揭示了Fam13a可能通过抑制EMT在肺纤维化发展中起关键作用,因此Fam13a在IPF治疗中具有治疗潜力。